Placebo News and Research

RSS

Drug for children with sickle cell anemia reduces hospitalizations and treatment costs

A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears today in the advance online edition of the journal Pediatrics.

2 Sep 2013

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial.

2 Sep 2013

Ipsen announces results of phase III study of somatuline in patients with neuroendocrine tumors

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the detailed results of phase III CLARINET study assessing the effect of Somatuline® Autogel® 120 mg in patients with gastrointestinal and pancreatic neuroendocrine tumors ("GEP-NETs")1 will be disclosed for the first time on September 28, 2013 at the European Cancer Congress 2013 (Sept. 27 - Oct. 1, 2013) in Amsterdam.

31 Aug 2013

Meda signs agreement to acquire Acton Pharmaceuticals, Inc

Meda has signed an agreement to acquire the US development company Acton Pharmaceuticals, Inc. ("Acton") including the proprietary product Aerospan. Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide.

31 Aug 2013

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined 9 biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis in whom prior pharmacological treatment had failed.

31 Aug 2013

European Commission approves Stivarga tablets for treatment of patients with mCRC

Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the European Commission has approved Stivarga® (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC).

30 Aug 2013

Alcohol reduces communication in areas of brain responsible for perceiving social cues

Alcohol intoxication reduces communication between two areas of the brain that work together to properly interpret and respond to social signals, according to researchers at the University of Illinois at Chicago College of Medicine.

30 Aug 2013

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease in patients with mild dyslipidemia.

30 Aug 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

Testosterone improves exercise capacity in men with COPD

A systematic review and meta-analysis confirms that testosterone therapy improves exercise capacity in men with chronic obstructive pulmonary disease.

28 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

FDA extends PDUFA goal date for Auxilium Pharmaceuticals' sBLA for XIAFLEX

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has notified the Company that it is extending the Prescription Drug User Fee Act goal date for the Company's supplemental biologics license application for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease from September 6, 2013 to December 6, 2013.

28 Aug 2013

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network, are published today in The Lancet Diabetes & Endocrinology.

28 Aug 2013

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

Today Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of psoriasis.

27 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Mount Sinai scientists receive NIH grant to study clinical benefit of IGF-1 in children with PMS

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health to study Insulin-Like Growth Factor-1, a promising treatment for a subtype of autism called Phelan McDermid Syndrome.

27 Aug 2013

Sangamo BioSciences signs definitive agreement to buy Ceregene

Sangamo BioSciences, Inc. announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

26 Aug 2013

Scientists receive NIH grant to study commercially-available drug for treatment of PMS

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health (NIH) to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for a subtype of autism called Phelan McDermid Syndrome (PMS).

26 Aug 2013

Aromatherapy, IV dextrose may relieve nausea and vomiting after surgery

Two simple, non-drug treatments-aromatherapy and intravenous administration of a simple sugar solution-may offer effective new approaches to relieving nausea and vomiting after surgery, report a pair of studies in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

22 Aug 2013

Appetite-Controlling Hormone Leaves Obese People Still Hungry

...

22 Aug 2013

Placebo News and Research

Drug for children with sickle cell anemia reduces hospitalizations and treatment costs

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

Ipsen announces results of phase III study of somatuline in patients with neuroendocrine tumors

Meda signs agreement to acquire Acton Pharmaceuticals, Inc

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

European Commission approves Stivarga tablets for treatment of patients with mCRC

Alcohol reduces communication in areas of brain responsible for perceiving social cues

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Testosterone improves exercise capacity in men with COPD

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

FDA extends PDUFA goal date for Auxilium Pharmaceuticals' sBLA for XIAFLEX

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

FDA grants Priority Review designation to sNDA for Nexavar tablets

Mount Sinai scientists receive NIH grant to study clinical benefit of IGF-1 in children with PMS

Sangamo BioSciences signs definitive agreement to buy Ceregene

Scientists receive NIH grant to study commercially-available drug for treatment of PMS

Aromatherapy, IV dextrose may relieve nausea and vomiting after surgery

Appetite-Controlling Hormone Leaves Obese People Still Hungry

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News